Development

• Elon Musk stated Tesla and SpaceX AI will continue large Nvidia chip purchases even as Tesla advances its AI5 chip, optimized for edge compute in Optimus and Robotaxi. • Tesla's Terafab AI chip manufacturing facility is set to launch within seven days from March 14, potentially by March 21. • Musk praised Nvidia CEO Jensen Huang, noting AI5's efficiency in half-reticle format could halve fab needs, with AI6 potentially matching dual AI5.

• The U.S. Department of Defense designated Quantum and Battlefield Information Dominance (Q-BID) as one of six critical technology areas in November 2025, with the Quantum Applications Program receiving $59.5 million in the FY 2026 National Defense Authorization Act. • Quantum computing, sensing, and networking have advanced at the research level, but substantial gaps remain between laboratory demonstrations and industrial deployment, particularly in miniaturization, durability, and production cost reduction for quantum sensors. • The United States maintains classical computing leadership but faces gaps in quantum-supercomputer deployment compared to international competitors, with Europe and Japan reaching operational quantum-supercomputer deployment stages that U.S. initiatives have not yet achieved.

• Bell's stop-fold tiltrotor uncrewed aircraft for DARPA's Speed and Runway Independent Technologies (Sprint) project Phase 2 has been officially designated the X-76. • The demonstrator aims to achieve high-speed vertical takeoff and landing capabilities, marking a key advancement in aerospace technology. • Coverage highlights emerging technologies including Sikorsky's hybrid powertrain tests and light-driven sustainable aviation fuel production.

An FDA advisory committee has recommended the development of next year's flu vaccine, as new data from the CDC indicates the current 2025-2026 flu vaccine provides moderate protection against hospitalization for vaccinated individuals despite concerns about late-emerging H3N2 strains. The committee reviewed winter flu shot effectiveness reports published in the CDC's online MMWR journal, which showed moderate protective efficacy against severe outcomes requiring hospitalization. The timing of vaccine selection remains critical as late-emerging H3N2 variants can significantly undermine vaccine effectiveness, a concern flagged by the committee during this year's review. Current guidance continues to emphasize vaccination for those at high risk of severe illness, particularly elderly and immunocompromised populations.